
NRIX Stock Forecast & Price Target
NRIX Analyst Ratings
Bulls say
Nurix Therapeutics is viewed positively because its lead BTK degrader bexobrutideg is advancing through registrational and combination studies in CLL while also expanding into high-value inflammatory indications, which broadens the addressable market and strengthens the platform thesis. The company’s 3Q26 results showed $673.1 million in revenue, $4.73 in EPS, and $1.1 billion in cash and cash equivalents, indicating strong non-dilutive funding and a runway into 2H29 despite higher one-time Roche-related SG&A. Additional upside comes from a diversified partnered pipeline, including NX-1607, IRAK4, and STAT6, plus collaboration validation from Roche, Gilead, Sanofi, and Pfizer.
Bears say
Nurix Therapeutics is viewed negatively because the downside case hinges on bexobrutideg failing to show competitive durability or raising a safety concern, outcomes that could halt further development and severely impair investor confidence. In that scenario, the stock could migrate toward the company’s net cash position with only minimal pipeline value attributed to its broader platform, underscoring how dependent the valuation is on a single clinical asset. With no evidence in the excerpt of offsetting revenue, diversification, or commercial traction, the company’s single-segment, clinical-stage profile leaves it highly exposed to binary drug-development risk.
This aggregate rating is based on analysts' research of Nurix Therapeutics, Inc and is not a guaranteed prediction by Public.com or investment advice.
NRIX Analyst Forecast & Price Prediction
Start investing in NRIX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Nurix Therapeutics, Inc (NRIX) Forecast
NRIX Analyst Forecast & Price Prediction
Start investing in NRIX
Order type
Buy in
Order amount
Est. shares
0 shares